Dominic Tang , David Shepherd, Andrew Belli, Vicki Fung, Eric Hansen, Xiaoqi Geng, Ching-Kun Wang
Primary treatment options for patients with high-risk non-metastatic prostate cancer (CaP) include radical prostatectomy or radiation therapy. The optimal treatment approach remains debated in the real-world practice setting due to lack of randomized controlled trial data. The objective of this study is to investigate the time to metastatic disease (TTM) development among patients treated with surgery, radiation or combination therapy in a real-world dataset.